Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Cream in Children Aged 2-11 Years With Non-segmental Vitiligo
NCT07595939Phase 3Not yet recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ruxolitinib cream in Vitiligo, sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoints: Proportion of participants achieving >=75% improvement from baseline in the Facial Vitiligo Area Scoring Index at 24 weeks and Total-Vitiligo Area Scoring Index at 24 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
ruxolitinib cream
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT07595939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07595939.